[go: up one dir, main page]

DK3468990T3 - Anti-C5-antistoffer og anvendelser deraf - Google Patents

Anti-C5-antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK3468990T3
DK3468990T3 DK17731785.6T DK17731785T DK3468990T3 DK 3468990 T3 DK3468990 T3 DK 3468990T3 DK 17731785 T DK17731785 T DK 17731785T DK 3468990 T3 DK3468990 T3 DK 3468990T3
Authority
DK
Denmark
Prior art keywords
antibodies
Prior art date
Application number
DK17731785.6T
Other languages
English (en)
Inventor
Ying Hu
Adrianna Latuszek
Carmelo Romano
William Olson
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3468990T3 publication Critical patent/DK3468990T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
DK17731785.6T 2016-06-14 2017-06-13 Anti-C5-antistoffer og anvendelser deraf DK3468990T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662349705P 2016-06-14 2016-06-14
US201662405561P 2016-10-07 2016-10-07
US201662422107P 2016-11-15 2016-11-15
PCT/US2017/037226 WO2017218515A1 (en) 2016-06-14 2017-06-13 Anti-c5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK3468990T3 true DK3468990T3 (da) 2024-06-24

Family

ID=59091673

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17731785.6T DK3468990T3 (da) 2016-06-14 2017-06-13 Anti-C5-antistoffer og anvendelser deraf

Country Status (29)

Country Link
US (4) US10633434B2 (da)
EP (2) EP3468990B1 (da)
JP (3) JP7102353B2 (da)
KR (3) KR20240070728A (da)
CN (3) CN109563159B (da)
AU (2) AU2017283470B2 (da)
CA (1) CA3027487A1 (da)
CL (1) CL2018003563A1 (da)
CO (1) CO2018014413A2 (da)
DK (1) DK3468990T3 (da)
ES (1) ES2984352T3 (da)
FI (1) FI3468990T3 (da)
HR (1) HRP20240815T1 (da)
HU (1) HUE067224T2 (da)
IL (2) IL263481B2 (da)
LT (1) LT3468990T (da)
MA (1) MA45235B1 (da)
MD (1) MD3468990T2 (da)
MX (3) MX2018015149A (da)
MY (3) MY196006A (da)
PH (2) PH12023500007A1 (da)
PL (1) PL3468990T3 (da)
PT (1) PT3468990T (da)
RS (1) RS65633B1 (da)
SG (2) SG10202012243VA (da)
SI (1) SI3468990T1 (da)
SM (1) SMT202400269T1 (da)
UA (1) UA124734C2 (da)
WO (1) WO2017218515A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
HRP20240722T1 (hr) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
DK2328616T3 (da) * 2008-08-05 2015-07-20 Novartis Ag Sammensætninger og fremgangsmåder for antistoffer mod komplementprotein C5
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
IL263481B2 (en) * 2016-06-14 2024-06-01 Regeneron Pharma Antibodies against C5 and their uses
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JP7364221B2 (ja) * 2017-03-06 2023-10-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｃ５抗体およびその使用
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
AU2018354404A1 (en) 2017-10-26 2020-04-16 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
JP7390301B2 (ja) 2018-03-23 2023-12-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトｐｄ－ｌ２抗体およびその使用方法
SG11202009258RA (en) * 2018-03-23 2020-10-29 Univ Texas Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
SG11202110121VA (en) * 2018-04-26 2021-10-28 Univ Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
US20210214425A1 (en) * 2018-05-31 2021-07-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
MX2021002710A (es) * 2018-09-06 2021-09-23 Univ Pennsylvania Anticuerpos anti-c5 humanizados y usos de los mismos.
US20220056115A1 (en) * 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
WO2020061496A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Eculuzimab for the treatment of neuromyelitis opticae
CN112996561A (zh) 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
CN113614105A (zh) 2019-01-25 2021-11-05 亚力兄制药公司 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
MX2021009789A (es) 2019-02-14 2021-11-17 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
US20220227851A1 (en) * 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
CN116782876A (zh) * 2019-08-16 2023-09-19 瑞泽恩制药公司 高浓度抗c5制剂
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
IL291807A (en) * 2019-10-25 2022-06-01 Regeneron Pharma Dosing regimens for the treatment or prevention of c5-related diseases
WO2021118999A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
JP2023507852A (ja) 2019-12-23 2023-02-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
WO2021222549A1 (en) 2020-04-30 2021-11-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2021231470A1 (en) 2020-05-12 2021-11-18 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
CA3173011A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
EP4295905A1 (en) 2020-07-09 2023-12-27 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
MX2023001702A (es) 2020-08-13 2023-03-09 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).
AU2021344411A1 (en) 2020-09-21 2023-04-27 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)
JP2023548046A (ja) 2020-10-23 2023-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法
JP2024504366A (ja) 2021-01-22 2024-01-31 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2022265915A1 (en) 2021-06-14 2022-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm)
JP2024526742A (ja) 2021-07-14 2024-07-19 アレクシオン ファーマシューティカルズ， インコーポレイテッド 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
AU2022378567A1 (en) 2021-10-29 2024-04-11 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2024046234A1 (zh) * 2022-08-30 2024-03-07 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
CA2113089C (en) 1991-07-15 2007-11-06 Peter J. Sims Universal donor cells
WO1994000560A1 (en) 1992-06-29 1994-01-06 Alexion Pharmaceuticals, Inc. Matrix for universal donor microvascular endothelial cells
DE69533921T2 (de) 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
ES2252746T3 (es) 1994-09-23 2006-05-16 Alexion Pharmaceuticals, Inc. Procedimientos para el tratamiento de la enfermedad inflamatoria articular.
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
DE60140618D1 (de) 2000-10-10 2010-01-07 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60219801T3 (de) 2001-08-17 2016-06-16 Genentech, Inc. KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
JP4601426B2 (ja) 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
KR20090088973A (ko) 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
KR101076516B1 (ko) 2003-09-08 2011-10-24 파나소닉 주식회사 플라즈마 처리방법 및 장치
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
PT1755674E (pt) 2004-05-14 2015-02-05 Alexion Pharma Inc Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento
US7763708B2 (en) 2004-08-12 2010-07-27 Institute For Protein Science Co., Ltd. Methods and compositions for modulating C5-a-mediated inflammatory responses
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
AU2013200223B2 (en) 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
MX360959B (es) 2005-11-04 2018-11-23 Genentech Inc Uso de inhibidores de la vía del complemento para tratar enfermedades oculares.
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
KR20080110800A (ko) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
JP5695317B2 (ja) 2006-09-05 2015-04-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗体媒介性ニューロパシーを処置するための方法および組成物
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (en) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
EP2698166B1 (en) 2006-10-10 2015-09-30 Regenesance B.V. Complement inhibition for improved nerve regeneration
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
HRP20240722T1 (hr) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
US20100192170A1 (en) 2009-01-28 2010-07-29 Gregory G. Raleigh Device assisted service profile management with user preference, adaptive policy, network neutrality, and user privacy
AU2014201433B2 (en) 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
DK2328616T3 (da) * 2008-08-05 2015-07-20 Novartis Ag Sammensætninger og fremgangsmåder for antistoffer mod komplementprotein C5
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US9891219B2 (en) 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
EP2352517A4 (en) 2008-11-10 2013-01-16 Alexion Pharma Inc METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JP2012533771A (ja) 2009-07-17 2012-12-27 コーニング ケーブル システムズ リミテッド ライアビリティ カンパニー 光ファイバリボン及び低オリゴマー含有量を有するリボンマトリックス材料
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2521562B1 (en) 2010-01-08 2019-09-18 Volution Immuno Pharmaceuticals SA Ev576 for use in the treatment of viral infections of the respiratory tract
LT3095871T (lt) 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
JP5852021B2 (ja) 2010-03-01 2016-02-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド ドゴー病を処置するための方法および組成物
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
AU2015201676B2 (en) 2010-04-30 2016-10-13 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
RU2014152803A (ru) 2012-05-25 2016-07-20 Новартис Аг Водная фармацевтическая композиция, содержащая терапевтический агент и гуанидин, производное гуанидина, и инъекция, включающая эту композицию
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
CA2899589C (en) 2013-01-31 2022-02-22 Seoul National University R & Db Foundation C5 antibody and method for preventing and treating complement-related diseases
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR102448976B1 (ko) 2013-08-07 2022-09-29 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CA2921856A1 (en) 2013-09-16 2015-03-19 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
CA2926812A1 (en) 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
JP6619745B2 (ja) 2014-02-20 2019-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体
EP3107937A4 (en) 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN106132982A (zh) 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US10177705B2 (en) 2014-07-12 2019-01-08 Kaneka Corporation Composite solar cell, solar cell module, and concentrating solar cell
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
WO2016160756A2 (en) 2015-03-31 2016-10-06 Alexion Pharmaceuticlas, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents
EP3288586A1 (en) 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
US20160362482A1 (en) 2015-06-10 2016-12-15 Case Western Reserve University Compositions and methods of modulating b cell response
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017044811A1 (en) 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
JP2018528975A (ja) 2015-09-28 2018-10-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法
JP2018530574A (ja) 2015-10-07 2018-10-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の加齢黄斑変性を治療する方法
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
ES2986888T3 (es) 2015-10-30 2024-11-13 Alexion Pharma Inc Un método para inhibir las exacerbaciones de la vasculopatía del aloinjerto mediada por células T
TW202344514A (zh) 2015-12-18 2023-11-16 日商中外製藥股份有限公司 抗c5抗體及使用方法
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN109475630A (zh) 2016-05-27 2019-03-15 瑞颂医药公司 治疗难治性全身型重症肌无力的方法
WO2017212391A1 (en) 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
JP2019521105A (ja) 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Antibodies against C5 and their uses
EA201990018A1 (ru) 2016-06-17 2019-08-30 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
US11303992B2 (en) 2016-07-06 2022-04-12 Macho Daisy, Llc. Wearable device and system for personal audio messaging
EP3512964B1 (en) 2016-09-14 2021-12-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease
WO2018071624A1 (en) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US10802945B2 (en) 2016-12-07 2020-10-13 Ab Initio Technology Llc Differencing of executable dataflow graphs
EP3554543A4 (en) 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION
KR101949891B1 (ko) 2017-01-31 2019-02-19 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
JP7364221B2 (ja) 2017-03-06 2023-10-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｃ５抗体およびその使用
JP7251792B2 (ja) 2017-03-23 2023-04-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗Ｃ５ａ抗体とその使用
JP2020517605A (ja) 2017-04-19 2020-06-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
CN111201241A (zh) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
CN116782876A (zh) 2019-08-16 2023-09-19 瑞泽恩制药公司 高浓度抗c5制剂

Also Published As

Publication number Publication date
AU2024204175A1 (en) 2024-07-11
BR112018075875A2 (pt) 2019-03-19
IL263481B2 (en) 2024-06-01
SI3468990T1 (sl) 2024-07-31
KR20190018166A (ko) 2019-02-21
ES2984352T3 (es) 2024-10-29
AU2017283470B2 (en) 2024-03-21
PH12023500007A1 (en) 2024-03-11
JP2023175765A (ja) 2023-12-12
CN116769024A (zh) 2023-09-19
US20200262901A1 (en) 2020-08-20
MY191668A (en) 2022-07-06
IL263481A (en) 2019-01-31
CN116751293A (zh) 2023-09-15
CA3027487A1 (en) 2017-12-21
AU2017283470A1 (en) 2019-01-03
JP7368543B2 (ja) 2023-10-24
KR102667023B1 (ko) 2024-05-21
KR20240070728A (ko) 2024-05-21
MD3468990T2 (ro) 2024-11-30
US20200262900A1 (en) 2020-08-20
MY196220A (en) 2023-03-23
MX2018015149A (es) 2019-08-21
IL309975A (en) 2024-03-01
US20170355757A1 (en) 2017-12-14
MX2023001726A (es) 2023-02-22
KR20230074831A (ko) 2023-05-31
HUE067224T2 (hu) 2024-10-28
US11492392B2 (en) 2022-11-08
EP3468990A1 (en) 2019-04-17
US20230174631A1 (en) 2023-06-08
EP4374922A3 (en) 2024-08-28
RS65633B1 (sr) 2024-07-31
MA45235A (fr) 2019-04-17
MY196006A (en) 2023-03-06
HRP20240815T1 (hr) 2024-09-27
JP2019528039A (ja) 2019-10-10
PH12018502560A1 (en) 2019-10-14
SG10202012243VA (en) 2021-01-28
EP3468990B1 (en) 2024-03-27
KR102534895B1 (ko) 2023-05-24
MA45235B1 (fr) 2024-07-31
JP2022106952A (ja) 2022-07-20
PT3468990T (pt) 2024-06-25
MX2023001727A (es) 2023-02-22
JP7102353B2 (ja) 2022-07-19
US11479602B2 (en) 2022-10-25
IL263481B1 (en) 2024-02-01
CO2018014413A2 (es) 2019-03-08
FI3468990T3 (fi) 2024-06-26
US10633434B2 (en) 2020-04-28
LT3468990T (lt) 2024-06-25
CN109563159A (zh) 2019-04-02
EP4374922A2 (en) 2024-05-29
SG11201810933QA (en) 2019-01-30
CL2018003563A1 (es) 2019-02-22
SMT202400269T1 (it) 2024-07-09
PH12018502560B1 (en) 2023-11-15
UA124734C2 (uk) 2021-11-10
PL3468990T3 (pl) 2024-08-05
CN109563159B (zh) 2023-06-23
WO2017218515A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
DK3468990T3 (da) Anti-C5-antistoffer og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3347379T3 (da) Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL262095A (en) Anti-pacap antibodies and uses thereof
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
EP3592386A4 (en) ANTI-C5 ANTIBODIES AND THEIR USES
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
DK3107938T3 (da) Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3390442T5 (da) Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
DK3215527T3 (da) Humaniserede antikomplementfaktor c1q-antistoffer og anvendelser deraf
DK3359563T3 (da) Antigenreceptorer og anvendelser deraf